Entrada Therapeutics Ratios (2022-2025) | TRDA

Ratios Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -12.36%-66.49%41.30%22.08%42.84%61.03%-81.21%-1.94%-84.39%-2,201.28%-2,693.93%
EBIT Margin -22.88%-89.70%32.04%11.72%35.71%56.42%-110.67%-15.69%-105.99%-2,402.51%-2,915.18%
EBITDA Margin -20.82%-144.69%82.25%-21.16%39.00%58.03%-65.05%0.31%-82.06%-2,212.31%-2,720.76%
Operating Margin -22.88%-89.70%32.04%11.72%35.71%56.42%-110.67%-15.69%-105.99%-2,402.51%-2,915.18%
Net Margin -26.62%-142.70%81.09%-22.70%39.74%58.07%-71.50%2.95%-84.39%-2,211.54%-2,737.30%
FCF Margin 798.62%-201.50%-59.31%-11.92%-44.58%40.96%-127.26%-86.21%-192.87%-1,526.36%-1,743.62%
Efficiency
Assets Average 306.31M285.19M263.26M363.81M484.78M489.51M477.11M490.02M546.40M568.28M540.46M506.40M467.63M430.84M
Equity Average 266.71M244.63M222.89M221.08M218.26M226.79M244.51M255.86M349.65M426.19M425.56M422.97M398.38M360.11M
Invested Capital 277.39M256.04M233.22M212.55M229.61M206.91M246.66M242.36M269.37M429.93M422.45M428.68M417.26M379.50M340.72M
Asset Utilization Ratio 0.070.090.180.270.330.440.380.390.340.170.14
Leverage & Solvency
Equity Ratio 0.880.870.850.840.480.420.510.520.530.740.760.810.860.850.83
Valuation
Enterprise Value -263.90M-244.25M-215.57M-45.16M-227.65M-79.74M-51.88M-67.60M-68.44M-185.25M-78.05M-101.21M-67.84M-72.48M-93.29M
Return Ratios
Return on Sales -0.27%-1.43%0.81%-0.23%0.40%0.58%-0.71%0.03%-0.84%-22.12%-27.37%
Return on Capital Employed -0.40%-0.37%-0.21%-0.10%-0.01%0.08%0.20%0.12%0.09%0.01%-0.21%-0.30%
Return on Invested Capital -0.38%-0.43%-0.15%0.01%0.05%0.25%0.10%0.11%0.01%-0.23%-0.33%
Return on Assets -0.36%-0.22%-0.17%-0.04%-0.01%0.05%0.19%0.10%0.12%0.05%-0.16%-0.24%
Return on Equity -0.42%-0.36%-0.38%-0.10%-0.03%0.09%0.30%0.13%0.15%0.06%-0.18%-0.29%